Drug Trial Radar · NCT00557921
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
Last checked: Nov 19, 2026Latest source record: Jan 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5,000
Planned (sponsor's estimate)
Start
Dec 2007
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Cogentus PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease, in the setting of concomitant aspirin therapy. Antiplatelet therapy is an essential element of care for patients with atherothrombotic disease. Bleeding is a fundamental adverse effect of all antiplatelet drugs including aspirin, clopidogrel and dual antiplatelet regimens. The gastrointestinal tract is the most common site of bleeding related to antiplatelet therapy, typically in connection with peptic ulcer disease. Recently published studies suggest the use of clopidogrel carries a gastrointestinal bleeding risk similar to that of aspirin or non-aspirin non-steroidal anti-inflammatory drugs. Patients taking any two of these drugs (clopidogrel, aspirin and/or non-aspirin NSAIDs) are exposed to an even higher risk of bleeding and ulcer disease. Cogentus Pharmaceuticals is launching phase 3 trials of a novel combination product, CGT-2168, which has the potential to significantly reduce this problem and increase patient safety. CGT-2168 combines a standard dosage of clopidogrel and a gastroprotectant (omeprazole) in a once-daily pill that may reduce the likelihood of adverse gastrointestinal events.
Conditions
- Acute Coronary Syndrome
- Myocardial Infarction
- Coronary Artery Disease
- Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirinDrug
(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Plavix (clopidogrel 75 mg) and aspirinDrug
(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforationTime frame: Anticipated minimum of 48 weeks, up to end of study
Locations
491 sites in 16 countries. Site status is shown where the registry gives one.
Alabama Clinical Research Institute, Inc. (ACRI)
Alexander City, Alabama
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Cardio-Thoracic Surgeons P.C.
Birmingham, Alabama
Birmingham Heart Clinic, PC
Birmingham, Alabama
John F Simmons , MD PC
Geneva, Alabama
Clinical Research Consultants, Inc.
Hoover, Alabama
The Heart Center, PC
Huntsville, Alabama
Mobile Heart Specialists, PC
Mobile, Alabama
Advanced Cardiac Specialists
Mesa, Arizona
Redpoint Research
Phoenix, Arizona
Cardiovascular Consultants, Ltd.
Phoenix, Arizona
Cochise Clinical Research
Sierra Vista, Arizona
Paradigm Clinical Research, Inc.
Tucson, Arizona
Tri-Lakes Research
Hot Springs, Arkansas
Michael A. Frais, Cardiologist, P.A.
Hot Springs, Arkansas
NEA-Clinic Cardiology
Jonesboro, Arkansas
Searcy Medical Center
Searcy, Arkansas
Cardiology Consultants of Orange County
Anaheim, California
Chest and Critical Care Consultants, A Medical Group
Anaheim, California
Clinical Solutions Advantage
Buena Park, California
Turns Institute for Clinical Research
Castro Valley, California
Escondido Cardiology Associates
Escondido, California
Accurate Clinical Trials, Inc.
Laguna Hills, California
Therapeutic Research Institute of Orange County
Laguna Hills, California
Kirtik Thaker MD
Lakewood, California
Los Angeles Cardiology Associates
Los Angeles, California
Merced Heart Associates
Merced, California
Mission Internal Medical Group
Mission Viejo, California
Altos Cardiovascular Associates
Mountain View, California
Kenneth W. Carr, MD, Cardiology
Oceanside, California
Rancho CucamongaClinical Trials
Rancho Cucamonga, California
Inland Heart and Vascular Medical Associates
San Bernardino, California
Ritchken and First
San Diego, California
Rider Research Group
San Francisco, California
Richard Levy, MD.
San Francisco, California
Kaiser Permanente
San Jose, California
Medical Helping Hands Research
Santa Ana, California
Pacific Heart Institute
Santa Monica, California
Radiant Research
Santa Rosa, California
Harbor- UCLA Medical Center
Torrance, California
Showing 40 of 491 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.